Concepedia

Victoria Ebiana

VE

Statistics

Publications

10

Citations

1.2K

H-Index

10

Active since

2012

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

University of California, Los Angeles

Okayama University Hospital

Hyogo Prefectural Cancer Center

Kansai Medical University

Victoria Ebiana is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, oncology, and pembrolizumab therapy.

Publications per year

2012–2021

10

Publications

10

Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study

Charles M. Rudin, Mark M. Awad, Alejandro Navarro et al. · Journal of Clinical Oncology · 2020 · 759 citations · Full text

, , +14

Patient-Specific Metrics of Invasiveness Reveal Significant Prognostic Benefit of Resection in a Predictable Subset of Gliomas

Anne Baldock, Sunyoung Ahn, Russell C. Rockne et al. · PLoS ONE · 2014 · 113 citations · Full text

, , +17

Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042

Aaron S. Mansfield, Roy S. Herbst, Gilberto de Castro et al. · JTO Clinical and Research Reports · 2021 · 82 citations · Full text

, , +17

OA14.01 KEYNOTE-024 3-Year Survival Update: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer

Martin Reck, Delvys Rodríguez‐Abreu, AE Robinson et al. · Journal of Thoracic Oncology · 2019 · 45 citations · Full text

, , +14

Defining Glioblastoma Resectability Through the Wisdom of the Crowd: A Proof-of-Principle Study

Adam M. Sonabend, Brad E. Zacharia, Michael Cloney et al. · Neurosurgery · 2016 · 44 citations · Full text

, , +13

1–5 of 10